Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Attilla Ting"'
Autor:
Mark J. O'Connor, Alan Lau, Keith W. Caldecott, Niall M.B. Martin, David Rudge, Jos Jonkers, Sven Rottenberg, Marina Pajic, Robert H. Bradbury, Attilla Ting, Bastiaan Evers, Charlotte Knights, Louise Jones, Janneke E. Jaspers, Henry Brown, Rajesh Odedra, Aaron N. Cranston, Stuart L. Rulten, Lenka Oplustil O'Connor
The PARP inhibitor AZD2461 was developed as a next-generation agent following olaparib, the first PARP inhibitor approved for cancer therapy. In BRCA1-deficient mouse models, olaparib resistance predominantly involves overexpression of P-glycoprotein
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2109b65c80b64c5dc8e0c07cc7793822
https://doi.org/10.1158/0008-5472.c.6508109
https://doi.org/10.1158/0008-5472.c.6508109
Autor:
Mark J. O'Connor, Alan Lau, Keith W. Caldecott, Niall M.B. Martin, David Rudge, Jos Jonkers, Sven Rottenberg, Marina Pajic, Robert H. Bradbury, Attilla Ting, Bastiaan Evers, Charlotte Knights, Louise Jones, Janneke E. Jaspers, Henry Brown, Rajesh Odedra, Aaron N. Cranston, Stuart L. Rulten, Lenka Oplustil O'Connor
Supplementary materials and methods. Suppl Table 1. MMS combination PF50 cell line assays. Concentration-dependent potentiation of MMS (PF50 ratios). Suppl Table 2. Permeability of AZD2461 and olaparib were assessed. Suppl Table 3. Activity of olapar
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::730097b7c140c8178ff65dd44a170b76
https://doi.org/10.1158/0008-5472.22410926.v1
https://doi.org/10.1158/0008-5472.22410926.v1
Autor:
Niall M. B. Martin, Bastiaan Evers, Charlotte Knights, Janneke E. Jaspers, Jos Jonkers, Attilla Ting, Henry Brown, Keith W. Caldecott, Sven Rottenberg, Rajesh Odedra, Lenka Oplustil O'Connor, Robert Hugh Bradbury, Aaron Cranston, David Alan Rudge, Mark J. O'Connor, Marina Pajic, Louise J. Jones, Alan Lau, Stuart L. Rulten
Publikováno v:
Cancer Research. 76:6084-6094
The PARP inhibitor AZD2461 was developed as a next-generation agent following olaparib, the first PARP inhibitor approved for cancer therapy. In BRCA1-deficient mouse models, olaparib resistance predominantly involves overexpression of P-glycoprotein
Autor:
Charlene Fallan, Derek Barratt, Gillian M. Lamont, Elaine Cadogan, Frederick W. Goldberg, Mercedes Vazquez-Chantada, Antonio Ramos Montoya, Anna Cronin, Simon J. Hollingsworth, Andrew D. Campbell, D. Beattie, Raymond AstraZeneca R D Alderley Finlay, Jacqueline H. L. Fok, Emma Dean, Joanna Harding, Jane Norris, Attilla Ting, Barry R. Davies
Publikováno v:
Cancer Research. 79:DDT01-02
DNA-dependent kinase (DNA-PK) plays an important role in the cellular response to DNA damage through the detection and repair of double strand breaks, and is a critical component of the DNA damage response (DDR). Double strand breaks can be induced b
Autor:
Andrew David Morley, Galith Karoutchi, Stefan Gerhardt, Attilla Ting, Chris De Savi, Nash Ian Alun, Ken Page
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 22:271-277
Directed screening has identified a novel series of non-zinc binding MMP13 inhibitors that possess good levels of activity whilst demonstrating excellent selectivity over related MMPs. A lead optimisation campaign has delivered compounds with enhance
Autor:
Michael James, Gordon A. Hamlin, Stefan Gerhardt, David Ryan, Nash Ian Alun, Attilla Ting, Stephen J. Norris, Galith Karoutchi, Chris De Savi, Neil Rankine, David J. Hargreaves, Christine M. Wood, Sarah V. Baker, Philip A. MacFaul, Andrew David Morley, Kostas Karabelas
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 21:4215-4219
Directed screening has identified a novel series of MMP13 inhibitors that possess good levels of activity whilst possessing excellent selectivity over related MMPs. The binding mode of the series has been solved by co-crystallisation and demonstrates
Autor:
Stefan Gerhardt, Andrew Pape, Christopher D. Davies, Attilla Ting, Scott G. Lamont, David Milne, Chris De Savi, Peter R. Moore, Jeremy N. Burrows, Yvonne Sawyer, Mark Mills, John G. Cumming, Calum Cook, Peter D. Smith
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 21:1376-1381
Two series of N-hydroxyformamide inhibitors of ADAM-TS4 were identified from screening compounds previously synthesised as inhibitors of matrix metalloproteinase-13 (collagenase-3). Understanding of the binding mode of this class of compound using AD
Autor:
Keith Allan Menear, Ian R. Hardcastle, Edward Jolyon Griffen, M. Raymond V. Finlay, Roger J. Griffin, Kate M. Clapham, Bernard T. Golding, Celine Cano, Attilla Ting, Turner Paul, Julia Bardos, Gail L. Young
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 21:966-970
Introduction of an O-alkoxyphenyl substituent at the 8-position of the 2-morpholino-4H-chromen-4-one pharmacophore enabled regions of the ATP-binding site of DNA-dependent protein kinase (DNA-PK) to be probed further. Structure-activity relationships
Autor:
Peter Newham, Eleanor Henshaw, Philip A. MacFaul, Keith Oldham, Andrew David Morley, Neil Rankine, Christine M. Wood, David Elliot, Ken Page, Attilla Ting, Paul T. Sharpe
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 19:4832-4835
A novel approach to inhibition of the alphavbeta3 integrin is described, which uses compounds designed to generate nM potency without using the arginine binding site.
Autor:
Roger J. Griffin, Celine Cano, Bernard T. Golding, Attilla Ting, Mark Frigerio, Keith Allan Menear, Julia Bardos, Christopher M. Bailey, Marc Geoffrey Hummersone, Kappusamy Saravanan, Kerry Shea, Ian R. Hardcastle, Caroline Richardson, Nicola J. Curtin, Pia Thommes, Graeme C. M. Smith, David R. Newell
Publikováno v:
Journal of medicinal chemistry. 56(16)
Analogues of (dibenzo[b,d]thiophen-4-yl)-2-morpholino-4H-chromen-4-one (NU7441), a potent inhibitor of DNA-dependent protein kinase (DNA-PK; IC50 = 42 ± 2 nM), have been synthesized in which water-solubilizing groups [NHCO(CH₂)nNR¹R², where n =